A routine blood count could contain a surprisingly broad warning signal for metabolic syndrome, according to a large analysis of U.S. health data. Researchers examining 15,846 adults who participated in the National Health and Nutrition Examination Survey, or NHANES, from 2013 through 2020 found that people with higher pan-immune-inflammation values were more likely to have metabolic syndrome. The association persisted after the investigators adjusted for a wide range of demographic, lifestyle and clinical factors, suggesting that the relationship was not explained simply by age, sex or body weight. Metabolic syndrome is not a single disease but a cluster of abnormalities—including abdominal obesity, elevated blood pressure, high blood sugar, high triglycerides and reduced levels of protective HDL cholesterol—that together raise the risk of cardiovascular disease, stroke and type 2 diabetes. Of the participants included in the analysis, 3,845 met the study’s definition of metabolic syndrome.

The biomarker at the center of the study, known as the pan-immune-inflammation value, or PIV, is designed to combine information from several types of blood cells into one numerical estimate of systemic inflammatory activity. It is generally calculated using platelet, neutrophil, monocyte and lymphocyte counts: platelet count multiplied by neutrophil count and monocyte count, divided by lymphocyte count. Each component reflects a different aspect of the body’s immune and inflammatory state. Neutrophils and monocytes are innate immune cells that can rise during inflammation, while lymphocytes represent an important arm of adaptive immunity. Platelets participate in clotting but also interact with immune cells and blood-vessel walls. By integrating these measurements, PIV may capture a more complex biological pattern than any one cell count or a simpler ratio such as the neutrophil-to-lymphocyte ratio.

The new analysis does not show that inflammation causes metabolic syndrome, nor does it establish that PIV can diagnose the condition. Instead, it identifies a statistical association in a nationally representative, cross-sectional dataset. The researchers divided participants into four groups, or quartiles, according to their PIV values and compared the prevalence of metabolic syndrome across those groups. They then used weighted statistical models designed to account for the complex sampling structure of NHANES, which combines interviews, physical examinations and laboratory measurements to represent the civilian U.S. population. The investigators applied multivariable logistic regression, sensitivity analyses, subgroup comparisons and restricted cubic spline modeling to explore whether the relationship remained after accounting for potential confounding factors and whether it followed a straight-line pattern.

Across four increasingly adjusted statistical models, higher PIV was consistently linked to greater odds of metabolic syndrome. In the least adjusted model, each increase in the analyzed PIV measure was associated with an odds ratio of 1.19, with a 95 percent confidence interval from 1.13 to 1.26. After additional variables were introduced, the association remained statistically significant: the odds ratios were 1.17, 1.19 and finally 1.12 in the most fully adjusted model. The last estimate had a 95 percent confidence interval of 1.04 to 1.19 and a P value of 0.002. An odds ratio above one indicates higher odds of the outcome, although it should not be interpreted as a direct increase in an individual’s absolute risk. The confidence intervals also indicate uncertainty around each estimate; because they did not cross one, the researchers considered the associations statistically significant.

The pattern was not perfectly linear. Restricted cubic spline analysis, a flexible statistical technique that allows the data to curve rather than forcing them into a straight line, detected a nonlinear relationship between PIV and metabolic syndrome, with a P value of 0.044 for nonlinearity. This suggests that the change in metabolic-syndrome odds may not be identical at every point on the PIV scale. In biological terms, inflammation could have different implications at relatively low, intermediate or very high levels, or the association could reflect interactions with obesity, insulin resistance, liver dysfunction, kidney disease or medication use. The analysis found a positive relationship across the PIV range, but the detailed shape of that relationship would need to be tested in prospective studies before it could guide clinical thresholds.

To examine whether the result was being driven by specific types of participants, the researchers performed stratified analyses across subgroups. The positive association between PIV and metabolic syndrome remained broadly consistent, rather than disappearing in one particular demographic or clinical category. The investigators also repeated the analysis after excluding people taking fibrates or omega-3 products, which can affect blood lipids, as well as medications used to lower blood glucose or blood pressure. In that restricted sample, the association became stronger, with an odds ratio of 1.73 and a 95 percent confidence interval from 1.26 to 2.38. This finding may indicate that treatment-related changes in metabolic measurements or blood-cell profiles had partly obscured the relationship in the full dataset, although it could also reflect differences between people who do and do not receive those medications.

The researchers tested additional definitions and methods to assess the robustness of their findings. PIV remained significantly and positively associated with metabolic syndrome when the condition was defined using the Harmonized criteria, an internationally developed approach that brings together several commonly used diagnostic thresholds. Missing data were also addressed using random forest imputation, a machine-learning method that estimates absent values from patterns in the observed data. With that approach, the association remained stable in the first three models but weakened in the most fully adjusted model. Such attenuation is important: it shows that the strength of the association can depend on how missing information and potential confounders are handled, even when the overall signal remains suggestive.

Metabolic syndrome has long been linked to chronic, low-grade inflammation. Excess visceral fat—the metabolically active fat stored around internal organs—can release inflammatory signaling molecules and attract immune cells. These signals may interfere with insulin action, promote abnormal lipid metabolism and impair the function of the vascular endothelium, the cell layer lining blood vessels. Insulin resistance can lead the pancreas to produce more insulin to maintain normal blood glucose, while the liver may continue releasing glucose and producing triglyceride-rich particles. At the same time, inflammation and oxidative stress can alter platelet activity and leukocyte behavior. A composite measure such as PIV could therefore reflect several biological processes that overlap with the development or expression of metabolic syndrome, although it cannot reveal which process comes first.

The potential appeal of PIV is practical as much as biological. Platelet and white-cell counts are routinely included in complete blood counts, making the components relatively inexpensive and widely available compared with specialized inflammatory assays. If future research confirms that PIV adds meaningful information beyond waist circumference, blood pressure, glucose and lipid measurements, it could become a supplementary risk marker for identifying people who warrant closer metabolic evaluation. But the current study is not sufficient to support that use. NHANES provides a powerful population snapshot, yet its cross-sectional design measures exposure and outcome at roughly the same time. The data cannot establish whether elevated PIV precedes metabolic syndrome, results from it, or is influenced by an unmeasured factor such as infection, smoking, diet, medication, chronic disease or socioeconomic conditions.

The authors, led by Qian Dai and colleagues at Shanghai Fifth People’s Hospital affiliated with Fudan University and Fudan University’s Center for Community-Based Health Research, conclude that higher PIV is positively associated with the presence of metabolic syndrome among U.S. adults. They emphasize that prospective cohort studies in diverse populations are needed to determine whether the biomarker can predict future metabolic syndrome and whether it offers advantages over established measures of inflammation and insulin resistance. Clinical trials would also be needed to learn whether changing PIV through lifestyle or medical treatment changes metabolic outcomes, rather than merely accompanying them. For now, the study adds PIV to a growing list of inflammation-related indicators connected with cardiometabolic health. Its most important message is not that a single blood index can replace standard screening, but that the immune system, blood cells and metabolism may be more tightly intertwined than conventional checkups reveal.

Body mass index, a widely recognized indicator of body fat, serves as a key measure in epidemiological studies. Obesity has long been implicated in the development of various metabolic disorders, including impaired fasting glucose, a precursor to Type 2 diabetes. What makes this study particularly interesting is the focus on the neutrophil-to-lymphocyte ratio, a biomarker that reflects systemic inflammation often overlooked in dietary and lifestyle-related health assessments. Recognizing the intersection of these variables opens new avenues for research and potential interventions.

The research team meticulously recruited participants and tracked their health metrics over five years. This longitudinal approach offers a richer understanding of the dynamics at play—unlike cross-sectional studies that provide only a snapshot. Long-term data allow researchers to observe trends and associations over time, making the results more robust and compelling. The study involved assessing participants’ BMI, NLR, and fasting glucose levels, capturing a comprehensive picture of their health progression.

Initial findings revealed a notable correlation between increased BMI and elevated NLR levels, indicating that overweight and obese individuals tend to exhibit a heightened inflammatory response. This is particularly crucial as chronic inflammation is a known factor contributing to insulin resistance and impaired glucose metabolism. The data suggests that as individuals gain weight, their immune response may shift in ways that directly impact their ability to regulate blood sugar levels adequately.

What’s particularly novel about these findings is the mediating role of BMI in the relationship between NLR and impaired fasting glucose. Essentially, the data indicates that NLR does not directly initiate impaired glucose response; instead, it is the individual’s BMI that amplifies this association. Understanding this mediation can radically alter prevention strategies for those at risk of developing diabetes. It suggests that targeting body weight might mitigate the adverse effects of inflammation on glucose metabolism more effectively than previously thought.

The implications of this research extend beyond academic interest; they hold the potential to influence public health strategies. With rates of obesity escalating globally, understanding the biological mechanisms at play is critical for developing targeted interventions. For instance, lifestyle modifications aimed at weight reduction, such as improved dietary habits and increased physical activity, could diminish inflammation and therefore improve metabolic outcomes.

In analyzing the data, Liu and colleagues employed advanced statistical methods to ensure the accuracy and reliability of their findings. Through regression models, they were able to control for various confounding factors such as age, gender, and lifestyle, thus isolating the effects of BMI and NLR on fasting glucose levels. Such rigorous methodologies lend credibility to their conclusions and pave the way for further investigations into the links between inflammation and metabolic disorders.

Interestingly, the study also highlights the potential of NLR as a simple, cost-effective marker for identifying individuals at higher risk of metabolic diseases. As NLR can be derived from routine blood tests, it presents a feasible option for healthcare providers seeking to implement early intervention strategies. By identifying at-risk populations through NLR measurements, targeted lifestyle changes could be recommended, effectively disrupting the cycle before glucose impairment manifests.

The five-year follow-up provided not only insight into treatment efficacy but also brought forth questions about the reversibility of impaired glucose states. Can reduced inflammation through weight loss lead to normalized glucose levels? The evidence suggests a promising possibility. Participants who successfully lowered their BMI also experienced significant reductions in NLR and improvements in fasting glucose levels, hinting at the body’s remarkable ability to heal when faced with lifestyle changes.

As the scientific community aims to combat the burgeoning diabetes epidemic, studies such as these are invaluable. They underscore the importance of a multifaceted approach that considers not only weight management but also the inflammatory pathways that contribute to disease. By integrating this knowledge into clinical practice, healthcare professionals can offer more comprehensive care for patients struggling with obesity and metabolic dysfunction.

Lastly, as this research garners attention, it encourages further exploration into additional biomarkers that may interact with BMI and metabolic health. Future studies could expand on these findings by incorporating genetic, environmental, and lifestyle factors, creating a more exhaustive profile of what influences fasting glucose levels. The quest to understand and manage diabetes is far from over, and investigations such as the one conducted by Liu, Wu, and Peng are pivotal stepping stones toward holistic health solutions.

In summary, Liu et al.’s findings present a clear message: managing body weight is not just about aesthetics; it plays a critical role in our overall metabolic health. With a focus on inflammation as a key player in this narrative, the research opens exciting avenues for potential interventions. As we move forward, adopting a more integrated approach to tackling obesity could serve as an effective strategy in reducing the burden of diabetes and improving public health outcomes at large.

Subject of Research: The mediation effect of body mass index on the relationship between neutrophil-to-lymphocyte ratio and impaired fasting glucose.

Article Title: Body mass index mediates the association between neutrophil-to-lymphocyte ratio and impaired fasting glucose: evidence from a five-year follow-up study.

Article References: Liu, Y., Wu, B., Peng, G. et al. Body mass index mediates the association between neutrophil-to-lymphocyte ratio and impaired fasting glucose: evidence from a five-year follow-up study.
Sci Rep (2026). https://doi.org/10.1038/s41598-025-34721-w

Image Credits: AI Generated

DOI: 10.1038/s41598-025-34721-w

Keywords: Body mass index, neutrophil-to-lymphocyte ratio, impaired fasting glucose, inflammation, metabolic health.